Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities

v3.21.2
Accrued Expenses and Other Liabilities
6 Months Ended
Jun. 30, 2021
Accrued Expenses and Other Liabilities  
Accrued Expenses and Other Liabilities

8. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following:

June 30, 

December 31, 

    

2021

    

2020

Accrued preclinical and clinical trial expenses

$

873,042

$

628,000

Accrued manufacturing expenses

167,915

175,089

Compensation and related benefits

190,053

209,600

Accrued franchise tax

 

100,000

 

172,500

Other expenses

 

435,301

 

429,345

$

1,766,311

$

1,614,534